Daratumumab Plus Triplet Therapy for Transplant-Eligible Patients With Multiple Myeloma
Combination Therapy With Venetoclax in Resistant Multiple Myeloma
Early-Phase Trial of New Monoclonal Antibody Plus Pembrolizumab in Resistant Myeloma
Comparison of First-Line Treatments in Older Patients With Myeloma
How Does Facility and Provider Volume Impact Survival in Multiple Myeloma?
Comparing Health-Care Costs Across Lines of Therapy for Multiple Myeloma
Risk Assessment and Survival Prediction in Patients With Multiple Myeloma
Supportive Care for Older Adults With Myeloma: Underuse of Guideline Recommendations?
Insights on Individualizing Treatment of Patients with Multiple Myeloma
Redefining Value Propositions and Managed Care Considerations in Multiple Myeloma
Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?
Role of Proteasome Inhibitor Therapy in a Patient with High-Risk Relapsing Multiple Myeloma
City of Hope Comprehensive Cancer Center
The University of Texas MD Anderson Cancer Center
Roswell Park Cancer Institute
Fox Chase Cancer Center
Multiple Myeloma Research Foundation (MMRF)
NCCN-Funded Clinical Trials: Find a Clinical Trial
The Leukemia and Lymphoma Society